Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · Real-Time Price · USD

3.230

-0.090 (-2.71%)

At close: Aug 28, 2026, 4:00 PM EDT

3.230

0.00 (-0.01%)

After-hours: Aug 28, 2026, 7:30 PM EDT

-2.71% (1D)

Market Cap	269.41M +219.4%
Revenue (ttm)	11.04M +291.4%
Net Income	-88.73M
EPS	-1.40
Shares Out	83.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211,989
Open	3.320
Previous Close	3.320
Day's Range	3.200 - 3.380
52-Week Range	1.030 - 5.550
Beta	1.32
Analysts	Strong Buy
Price Target	7.22 (+123.53%)
Earnings Date	Aug 13, 2026

About PYXS

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 1, 2021

Employees 56

Stock Exchange NASDAQ

Ticker Symbol PYXS

Website https://www.pyxisoncology.com

Full Company Profile

Financial Performance

In 2025, Pyxis Oncology's revenue was $13.86 million, a decrease of -14.17% compared to the previous year's $16.15 million. Losses were -$79.62 million, 2.96% more than in 2024.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price target is $7.22, which is an increase of 123.53% from the latest price.

Price Target

$7.22

(123.53% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Pyxis Oncology files to sell 39.2M shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholders of up to 39.2M shares of common stock. The company is not selling any…

9 days ago - TheFly

Pyxis Oncology Registration statement: Registration filing

Pyxis Oncology filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.

9 days ago - Filings

Pyxis Oncology reports Q2 EPS (40c), consensus (35c)

“The second quarter was marked by continued execution across the MICVO program and a financing that strengthened our balance sheet and extended our cash runway into the second quarter of…

12 days ago - TheFly

Pyxis Oncology Slides: Corporate presentation

Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.

16 days ago - Filings

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data...

16 days ago - GlobeNewsWire

Pyxis Oncology Quarterly report: Q2 2026

Pyxis Oncology has published its Q2 2026 quarterly earnings report on August 13, 2026.

16 days ago - Filings

Pyxis Oncology Earnings release: Q2 2026

Pyxis Oncology released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.

16 days ago - Filings

Pyxis Oncology initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Pyxis Oncology (PYXS) with an Overweight rating and $12 price target The firm says dose capping likely addresses concerns on Micvo’s safety. In addition, the…

26 days ago - TheFly

Pyxis Oncology announces up to $114M private placement

Pyxis Oncology (PYXS) announced that it has entered into definitive securities purchase agreements for a private placement expected to result in gross proceeds of approximately $50M, before deducting ...

2 months ago - TheFly

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap

2 months ago - GlobeNewsWire

Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2026

A novel ADC targeting the tumor stroma is advancing in head and neck cancer, with mid-year data to clarify efficacy, safety, and regulatory path. Dose capping addresses safety in high body weight patients, and combination strategies are underway.

3 months ago - Transcripts

Pyxis Oncology Transcript: Stifel 2026 Targeted Oncology Virtual Forum

MICVO, an ADC targeting EDB-FN, has shown strong efficacy in head and neck cancer, with a 46–50% response rate at high doses and promising safety improvements via dose capping. Key monotherapy and combination data updates are expected mid-year and in the second half of the year.

3 months ago - Transcripts

Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026

MICVO, a novel ADC, has shown strong efficacy in second-line head and neck cancer, with a 46% response rate and promising safety improvements through dose capping. Ongoing trials and translational research support its potential in combination therapies and broader cancer indications.

3 months ago - Transcripts